Caplin Point Laboratories Ltd Q4 FY26 Results & Concall Highlights: Revenue, Margins & Order Book

Published 14 Jun 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹19.5K Cr

Caplin Point expects continued strong growth in pharmaceutical sales, particularly in Latin America and the US. Caplin Point Laboratories expects sustained strong growth over the next 3-5 years, considered their best period ahead.

From Caplin Point Laboratories Ltd's Q4 FY26 earnings-call transcript · updated 3 Sept 2026.

Price

₹2,835

Market Cap

₹19.5K Cr

P/E Ratio

29.3

How does Caplin Point Laboratories Ltd rank in Pharmaceuticals & Biotechnology?

Compare Caplin Point Laboratories Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Caplin Point Laboratories Ltd — Quarterly revenue & net profit

Revenue Net Profit

Dec 2024

Mar 2025

Jun 2025

Sep 2025

Dec 2025

Mar 2026

Reported quarterly figures (₹ Cr). Latest: revenue ₹600 Cr, net profit ₹173 Cr.

Full financials →

📊 Revenue & Sales Performance

→Caplin Point expects continued strong growth in pharmaceutical sales, particularly in Latin America and the US.
→Latin America growth may stabilize for 12-18 months due to regulatory product development timelines but is expected to rebound strongly thereafter.
→In the next 18-24 months, overall growth in Latin America sales is anticipated to return to double-digit rates.
→The US business is projected to sustain 20-25% growth driven by new ANDA approvals and expanding own-label products.
→Caplin Steriles business expects around 25-30% growth next year.
→Chile and Mexico markets are poised for significant expansion with increased product registrations and distribution.
→The company targets nearly doubling own-label sales from INR 100 crores to close to INR 200 crores in the coming year.
→Expansion into brand marketing in Central America is planned, enhancing product reach.
→Completion of capex projects will support scaling manufacturing and new market entries.

📈 Profitability & Margins

→Caplin Point Laboratories expects sustained strong growth over the next 3-5 years, considered their best period ahead.
→EBITDA margins are stable and expected to maintain or improve, with FY25-26 EBITDA at 30% and Q4 at 33% for CSL.
→PAT margins expected within 25%-29% during FY27-FY29, with confidence in maintaining double-digit revenue growth.
→Growth driven by expansion in regulated markets (USA, Mexico, Chile), new product launches, and completion of capex (more injectable lines planned).
→R&D investment increasing (5% of turnover), focusing on complex products.
→Cash flow strong, reserves and surplus expected to increase despite capex.
→Inorganic growth opportunities being selectively evaluated for acceleration.
→US business to continue strong growth (~20-25% expected) with significant order book visibility.
→Latin America expected to grow post product registrations, especially in Mexico and Chile.

See what Caplin Point Laboratories Ltd said on profitability & margins — free account, 30 seconds.

🏗️ Capital Expenditure Plans

→Residual capex of approximately INR 510 crores to be spent over the next 18-24 months, part of a larger INR 1,100 crores capex plan (50% completed).
→Ongoing projects include:
→ - Phase-III of injectable plant (POL-2).
→ - Construction of a larger capacity oral solids and derma facility in Pondicherry.
→ - Completion of oncology API plant.
→Plans for new facilities/buildings in Mexico and Chile, with execution starting by Q3 or Q4.
→Capex does not yet include inorganic growth plans like acquisitions or new warehouses/quality control labs in international markets.
→Despite ongoing capex, reserves and surplus are expected to continue rising due to strong cash generation.
→Future capex mostly focused on capacity expansion in regulated markets (USA, LATAM) and advanced manufacturing technologies.
→The company remains cash-rich, zero-leverage, and open to meaningful acquisitions.

💰 Fundraising & Capital Structure

→There is no mention of any current or planned fundraising through debt or equity in the provided transcript.
→The company states it is cash-rich with INR 1,471 crores in cash and INR 2,726 crores in liquid assets and is virtually debt-free.
→Management emphasized strengthening the balance sheet and using internal cash generation for ongoing capex (INR 1,100 crores planned, 50% completed).
→Future growth and acquisitions are expected to be funded from internal cash reserves.
→No specific plans for raising funds via equity or debt were indicated; focus is on organic growth, acquisitions, and capex using existing cash.
→The company is strategically prioritizing meaningful acquisitions but prefers not to take on vanity acquisitions, leveraging their strong financial position.

See what Caplin Point Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.

📋 Order Book & Pipeline

→Caplin Point Laboratories has a full order book for nearly six months.
→The company is seeing strong demand with no dearth of orders currently.
→Some lower-margin, high-volume products are being selectively declined to maintain profitability.
→Tender supplies, such as the large one in El Salvador (valued at about $16 million), have contributed to recent growth and increased receivables.
→Capacity utilization at facilities is optimal, indicating strong ongoing demand.
→The order book status supports the confidence in continuing strong growth for at least the next year for CSL (Caplin Steriles) and their own label business.

Key Metrics

What Caplin Point Laboratories Ltd's management said in earlier quarters

Q1 FY27 earnings call analysis →

Others in Pharmaceuticals & Biotechnology this season

Torrent Pharmaceuticals Ltd (Q4 FY26)
Consolidated revenue for Q4 FY26 up 42%, EBITDA up 41%, margins stable at ~32% (Page 2). Key concall takeaways from Torrent Pharma.'s Q4 FY26 earnings call…
Kwality Pharmaceuticals Ltd (Q4 FY26)
FY26: Achieved INR503 crores revenue; oncology contributed INR100-120 crores. Key concall takeaways from Kwality Pharmaceuticals Ltd's Q4 FY26 earnings call…
RPG Life Sciences Ltd (Q4 FY26)
Domestic formulation growth driven by strong volume expansion (~9.8% volume growth in Q4 FY26 vs 1.1% industry) and new product launches (5.1% growth vs 2%…
Sai Parenterals Ltd (Q4 FY26)
Long-term growth supported by over 50% revenue from long-term CDs contracts in regulated markets. Key concall takeaways from Sai Parenteral's's Q4 FY26…

Compare:vs Sun Pharma.Inds.vs Divi's Lab.vs Torrent Pharmaceuticals Ltd

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Frequently Asked Questions

What were Caplin Point Laboratories Ltd Q4 FY26 results?

What is Caplin Point Laboratories Ltd share price analysis?

Caplin Point Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 29.3 with a market cap of ₹19,465 Cr. Investors should review the full earnings analysis for detailed insights.

Is Caplin Point Laboratories Ltd planning capital expenditure?

Residual capex of approximately INR 510 crores to be spent over the next 18-24 months, part of a larger INR 1,100 crores capex plan (50% completed).

Keep Caplin Point Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.